Fidelity Investments’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$111M Buy
2,306,393
+953,773
+71% +$41M ﹤0.01% 1204
2026
Q1
$49.7M Sell
1,352,620
-8,664,705
-86% -$411M ﹤0.01% 1445
2025
Q4
$510M Sell
10,017,325
-4,058,066
-29% -$208M 0.03% 501
2025
Q3
$781M Buy
14,075,391
+134,231
+1% +$7.86M 0.04% 361
2025
Q2
$962M Buy
13,941,160
+4,308,228
+45% +$293M 0.05% 286
2025
Q1
$669M Sell
9,632,932
-388,952
-4% -$32.1M 0.04% 355
2024
Q4
$862M Sell
10,021,884
-7,909,693
-44% -$855M 0.05% 300
2024
Q3
$2.14B Sell
17,931,577
-1,563,065
-8% -$208M 0.13% 127
2024
Q2
$2.78B Buy
19,494,642
+1,890,320
+11% +$250M 0.18% 82
2024
Q1
$2.26B Buy
17,604,322
+4,941,097
+39% +$588M 0.15% 104
2023
Q4
$1.31B Buy
12,663,225
+585,724
+5% +$57.9M 0.1% 177
2023
Q3
$1.1B Buy
12,077,501
+1,231,727
+11% +$109M 0.09% 188
2023
Q2
$878M Buy
10,845,774
+882,786
+9% +$72.1M 0.07% 238
2023
Q1
$793M Buy
9,962,988
+1,623,508
+19% +$115M 0.07% 273
2022
Q4
$564M Buy
8,339,480
+7,035,342
+539% +$412M 0.06% 344
2022
Q3
$65M Sell
1,304,138
-101,072
-7% -$5.41M 0.01% 1135
2022
Q2
$78.3M Buy
1,405,210
+145,142
+12% +$8.05M 0.01% 1063
2022
Q1
$70M Buy
1,260,068
+175,564
+16% +$9.01M 0.01% 1254
2021
Q4
$60.7M Buy
1,084,504
+133,222
+14% +$7.22M ﹤0.01% 1346
2021
Q3
$45.7M Buy
951,282
+148,438
+18% +$7.18M ﹤0.01% 1450
2021
Q2
$33.6M Buy
802,844
+31,716
+4% +$1.23M ﹤0.01% 1609
2021
Q1
$26M Buy
771,128
+48,626
+7% +$1.73M ﹤0.01% 1685
2020
Q4
$25.2M Buy
722,502
+18,204
+3% +$629K ﹤0.01% 1604
2020
Q3
$24.4M Buy
704,298
+22,544
+3% +$751K ﹤0.01% 1487
2020
Q2
$22.3M Sell
681,754
-223,124
-25% -$7.12M ﹤0.01% 1504
2020
Q1
$27.2M Sell
904,878
-49,920
-5% -$1.49M ﹤0.01% 1279
2019
Q4
$27.6M Buy
954,798
+37,606
+4% +$1.04M ﹤0.01% 1474
2019
Q3
$23.7M Sell
917,192
-12,842
-1% -$325K ﹤0.01% 1506
2019
Q2
$23.7M Sell
930,034
-3,685,216
-80% -$91.1M ﹤0.01% 1549
2019
Q1
$121M Sell
4,615,250
-103,412
-2% -$2.54M 0.01% 829
2018
Q4
$109M Sell
4,718,662
-26,792
-0.6% -$595K 0.01% 816
2018
Q3
$112M Buy
4,745,454
+690,016
+17% +$16.8M 0.01% 904
2018
Q2
$93.5M Sell
4,055,438
-5,427,654
-57% -$129M 0.01% 989
2018
Q1
$234M Sell
9,483,092
-775,806
-8% -$20.4M 0.03% 620
2017
Q4
$275M Sell
10,258,898
-384,476
-4% -$9.78M 0.03% 564
2017
Q3
$256M Sell
10,643,374
-252,874
-2% -$5.71M 0.03% 586
2017
Q2
$234M Sell
10,896,248
-58,242
-0.5% -$1.18M 0.03% 621
2017
Q1
$188M Sell
10,954,490
-1,094,974
-9% -$19.1M 0.02% 717
2016
Q4
$216M Sell
12,049,464
-5,858,678
-33% -$106M 0.03% 633
2016
Q3
$372M Sell
17,908,142
-1,832,208
-9% -$45.4M 0.05% 419
2016
Q2
$531M Sell
19,740,350
-183,734
-0.9% -$5.04M 0.07% 290
2016
Q1
$540M Buy
19,924,084
+1,201,392
+6% +$32.2M 0.07% 272
2015
Q4
$544M Buy
18,722,692
+193,066
+1% +$5.34M 0.07% 281
2015
Q3
$503M Buy
18,529,626
+1,942,668
+12% +$55M 0.07% 299
2015
Q2
$454M Sell
16,586,958
-2,208,048
-12% -$62.1M 0.06% 361
2015
Q1
$502M Buy
18,795,006
+112,476
+0.6% +$2.59M 0.06% 345
2014
Q4
$395M Sell
18,682,530
-2,234,592
-11% -$49.9M 0.05% 403
2014
Q3
$498M Sell
20,917,122
-477,286
-2% -$11M 0.07% 319
2014
Q2
$494M Buy
21,394,408
+1,100,912
+5% +$24.3M 0.07% 327
2014
Q1
$463M Buy
20,293,496
+591,146
+3% +$12.6M 0.06% 334
2013
Q4
$364M Buy
19,702,350
+3,119,260
+19% +$54.4M 0.05% 394
2013
Q3
$281M Sell
16,583,090
-248,270
-1% -$4.18M 0.04% 474
2013
Q2
$261M Buy
+16,831,360
New +$280M 0.04% 481

Other funds holding NVO

Fidelity Investments's NVO Position: Q2 2026 in Review

Fidelity Investments increased its Novo Nordisk (NVO) stake by 71% in Q2 2026, buying an estimated $41M and bringing the position to 2,306,393 shares worth $111M. The position accounts for ﹤0.01% of the portfolio, ranked #1204.

Fidelity Investments first reported a position in NVO in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.78B in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Fidelity Investments held 2,306,393 shares of Novo Nordisk worth $111M as of Q2 2026.
  • Fidelity Investments bought 953,773 Novo Nordisk shares in Q2 2026, an estimated $41M.
  • Novo Nordisk made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #1204 holding.
  • Fidelity Investments first reported a position in Novo Nordisk in Q2 2013 and has held it in 53 quarters since.
  • Fidelity Investments's Novo Nordisk position peaked at $2.78B in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.